A combination therapy for KRAS-driven lung adenocarcinomas using lipophilic bisphosphonates and rapamycin
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
Lipophilic bisphosphonates combined with rapamycin inhibit the growth of KRAS -mutant lung adenocarcinomas in mouse models.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions
Ostrem, J. M., Peters, U., Sos, M. L., Wells, J. A., & Shokat, K. M. (2013) · Nature · doi:10.1038/nature12796 · Cited by 2,557 · cited 1×
“It is difficult to develop potent KRAS-mutant–specific inhibitors that can directly restore intrinsic GTPase activity, although specific inhibitors of KRAS G12C have recently been reported (6), as have attempts to interfere with mutated KRAS function by altering its membrane localization, inhibiting its downstream eff…”
Principles of cancer therapy: oncogene and non-oncogene addiction
Luo, J., Solimini, N. L., & Elledge, S. J. (2009) · Cell · doi:10.1016/j.cell.2009.02.024 · Cited by 1,765
Pancreatic cancers require autophagy for tumor growth
Yang, S., Wang, X., Contino, G., Liesa, M., Sahin, E., Ying, H., Bause, A., Li, Y., Stommel, J. M., Dell'Antonio, G., et al. (2011) · Genes & Development · doi:10.1101/gad.2016111 · Cited by 1,498
Activated Ras requires autophagy to maintain oxidative metabolism and tumorigenesis
Guo, J. Y., Chen, H.-Y., Mathew, R., Fan, J., Strohecker, A. M., Karsli-Uzunbas, G., Kamphorst, J. J., Chen, G., Lemons, J. M. S., Karantza, V., et al. (2011) · Genes & Development · doi:10.1101/gad.2016311 · Cited by 1,323
p53 status determines the role of autophagy in pancreatic tumour development
Rosenfeldt, M. T., O’Prey, J., Morton, J. P., Nixon, C., MacKay, G., Mrowinska, A., Au, A., Rai, T. S., Zheng, L., Ridgway, R., et al. (2013) · Nature · doi:10.1038/nature12865 · Cited by 713 · cited 1×
“Our results are more in line with those recently reported for pancreatic cancer (KRAS G12D and p53) development, where it was shown that another autophagy inhibitor, hydroxychloroquine, tended to accelerate tumor formation (35).”
Targeting protein prenylation for cancer therapy
Berndt, N., Hamilton, A. D., & Sebti, S. M. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3151 · Cited by 614 · cited 2×
“BPH-1222 treatment robustly inhibited protein farnesylation, as well as protein geranylgeranylation, as indicated by HRAS degradation and RAP1A dislodgement from the membrane fraction, respectively (27).”
Small molecule inhibition of the KRAS–PDEδ interaction impairs oncogenic KRAS signalling
Zimmermann, G., Papke, B., Ismail, S., Vartak, N., Chandra, A., Hoffmann, M., Hahn, S. A., Triola, G., Wittinghofer, A., Bastiaens, P. I. H., et al. (2013) · Nature · doi:10.1038/nature12205 · Cited by 596
Fisher, G. H., Wellen, S. L., Klimstra, D., Lenczowski, J. M., Tichelaar, J. W., Lizak, M. J., Whitsett, J. A., Koretsky, A., & Varmus, H. E. (2001) · Genes & Development · doi:10.1101/gad.947701 · Cited by 582 · cited 6×
“Lentiviral vector–mediated mouse lung cancer model and syngeneic graft model LSL-KRASG12D/+ Rosa26luc/luc mice were used for the lentiviral vector (CA2Cre-shp53) –mediated lung cancer model as described before (37).”
MethodInfluentialKRAS Mutations in Non-Small Cell Lung Cancer
Riely, G. J., Marks, J., & Pao, W. (2009) · Proceedings of the American Thoracic Society · doi:10.1513/pats.200809-107lc · Cited by 550
The Signaling Adaptor p62 Is an Important NF-κB Mediator in Tumorigenesis
Duran, A., Linares, J. F., Galvez, A. S., Wikenheiser, K., Flores, J. M., Diaz-Meco, M. T., & Moscat, J. (2008) · Cancer Cell · doi:10.1016/j.ccr.2008.02.001 · Cited by 541
Cited by
Role of Autophagy and Apoptosis in Non-Small-Cell Lung Cancer
Liu, G., Pei, F., Yang, F., Li, L., Amin, A., Liu, S., Buchan, J., & Cho, W. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18020367 · Cited by 425
K-Ras prenylation as a potential anticancer target
Baranyi, M., Buday, L., & Hegedűs, B. (2020) · Cancer and Metastasis Reviews · doi:10.1007/s10555-020-09902-w · Cited by 62
Liang, S.-Q., Bührer, E. D., Berezowska, S., Marti, T. M., Xu, D., Froment, L., Yang, H., Hall, S. R. R., Vassella, E., Yang, Z., et al. (2019) · Oncogene · doi:10.1038/s41388-018-0479-6 · Cited by 55
Guan, Y., Jiang, S., Ye, W., Ren, X., Wang, X., Zhang, Y., Yin, M., Wang, K., Tao, Y., Yang, J., et al. (2020) · Cell Death & Disease · doi:10.1038/s41419-020-03153-x · Cited by 34
Self-citation
Metadata
- Authors
- Xia, Y., Liu, Y.-L., Xie, Y., Zhu, W., Guerra, F., Shen, S., Yeddula, N., Fischer, W., Low, W., Zhou, X., Zhang, Y., Oldfield, E., & Verma, I. M.
- Venue
- Science Translational Medicine
- Published
- 2014-11-19
- Volume
- 6
- Issue
- 263
- Pages
- 263ra161-263ra161
- ISSN
- 1946-6234 (ISSN-L)
- 1946-6242
- OpenAlex
- W2115074961
- Cited by
- 55
- References
- 10
- FWCI
- 2.43
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A combination therapy for KRAS-driven lung adenocarcinomas using lipophilic bisphosphonates and rapamycin. https://app.cochat.ai/papers/10.1126/scitranslmed.3010382
- The paper
- Xia, Y., Liu, Y.-L., Xie, Y., Zhu, W., Guerra, F., Shen, S., Yeddula, N., Fischer, W., Low, W., Zhou, X., Zhang, Y., Oldfield, E., & Verma, I. M. (2014). A combination therapy for KRAS-driven lung adenocarcinomas using lipophilic bisphosphonates and rapamycin. Science Translational Medicine. https://doi.org/10.1126/scitranslmed.3010382
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.